GSK plc (NYSE:GSK) Position Increased by Nwam LLC

Nwam LLC grew its position in GSK plc (NYSE:GSK) by 126.4% during the 1st quarter, HoldingsChannel.com reports. The firm owned 16,080 shares of the pharmaceutical company’s stock after acquiring an additional 8,976 shares during the quarter. Nwam LLC’s holdings in GSK were worth $710,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently made changes to their positions in GSK. BKM Wealth Management LLC acquired a new stake in shares of GSK in the 4th quarter valued at $32,000. Dynamic Advisor Solutions LLC lifted its position in shares of GSK by 674.4% in the fourth quarter. Dynamic Advisor Solutions LLC now owns 55,384 shares of the pharmaceutical company’s stock worth $2,172,000 after buying an additional 48,232 shares during the last quarter. Whittier Trust Co. boosted its stake in shares of GSK by 107.6% during the 4th quarter. Whittier Trust Co. now owns 34,307 shares of the pharmaceutical company’s stock worth $1,271,000 after acquiring an additional 17,779 shares in the last quarter. Fortress Wealth Group LLC increased its holdings in shares of GSK by 11.2% during the 4th quarter. Fortress Wealth Group LLC now owns 8,605 shares of the pharmaceutical company’s stock valued at $341,000 after acquiring an additional 867 shares during the last quarter. Finally, SG Americas Securities LLC bought a new position in shares of GSK in the 4th quarter valued at approximately $119,000. 15.74% of the stock is owned by hedge funds and other institutional investors.

GSK Price Performance

NYSE:GSK opened at $39.35 on Friday. The company has a debt-to-equity ratio of 1.15, a current ratio of 0.87 and a quick ratio of 0.58. GSK plc has a one year low of $33.67 and a one year high of $45.92. The company has a fifty day moving average price of $41.38 and a 200 day moving average price of $41.41. The stock has a market cap of $81.55 billion, a P/E ratio of 14.26, a PEG ratio of 1.20 and a beta of 0.64.

GSK (NYSE:GSK) last announced its quarterly earnings data on Wednesday, May 1st. The pharmaceutical company reported $1.09 EPS for the quarter, beating analysts’ consensus estimates of $0.94 by $0.15. GSK had a net margin of 14.62% and a return on equity of 51.54%. The business had revenue of $9.34 billion during the quarter, compared to analyst estimates of $8.98 billion. Analysts anticipate that GSK plc will post 4.11 earnings per share for the current year.

GSK Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Thursday, July 11th. Shareholders of record on Friday, May 17th were issued a dividend of $0.3762 per share. This represents a $1.50 dividend on an annualized basis and a yield of 3.82%. This is an increase from GSK’s previous quarterly dividend of $0.36. The ex-dividend date was Thursday, May 16th. GSK’s payout ratio is presently 54.71%.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on the company. The Goldman Sachs Group started coverage on GSK in a research report on Thursday, May 30th. They set a “neutral” rating and a $47.00 target price for the company. Jefferies Financial Group upped their price objective on shares of GSK from $52.50 to $53.00 and gave the stock a “buy” rating in a report on Tuesday, July 2nd. Berenberg Bank upgraded shares of GSK to a “strong-buy” rating in a report on Thursday, June 20th. Citigroup upgraded shares of GSK to a “strong-buy” rating in a report on Monday, June 24th. Finally, UBS Group lowered GSK from a “buy” rating to a “neutral” rating in a research note on Monday, July 8th. Three investment analysts have rated the stock with a hold rating, two have issued a buy rating and three have given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Buy” and a consensus price target of $50.00.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.